- Opinion
- [Reporter's view] Revlimid passed the committee
- by Eo, Yun-Ho Jul 6, 2022 05:47am
- It is the first step forward in about four years. The maintenance therapy of the multiple myeloma treatment Revlimid has finally passed the Cancer Disease Review Committee. Maintenance therapy of Revlimid was approved in Korea in June 2018 and an application for expansion of insurance benefits was made in the same year. Since 2019, BMS has ac
- Company
- BL’s COVID-19 treatment expands indication to pneumonia
- by Lee, Seok-Jun Jul 6, 2022 05:47am
- BL is aiming to adopt an indication expansion strategy and develop 'BLS-H01,’ its new drug for COVID-19 treatment for which a Phase II trial is underway, as a broad-spectrum treatment for pneumonia. According to BL on the 5th, BLS-H01 is an immunoregulatory treatment that contains a gamma PGA. A clinical trial is currently underway to ass
- Company
- 2nd generation EGFR TKI Vizimpro can be prescribed in Big 5
- by Eo, Yun-Ho Jul 6, 2022 05:47am
- Pfizer's second-generation EGFR TKI Vizimpro has settled in the Big 5 General Hospital. According to related industries, Pfizer's EGFR TKI Vizimpro recently passed all five major medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, Asan Medical Center, and Sinchon Severance Hospit
- Company
- There are many complaints about the revaluation of generics
- by Chon, Seung-Hyun Jul 6, 2022 05:46am
- Pharmaceutical companies complain of unnecessary waste of money on products being sold without problems. Pharmaceutical companies are struggling ahead of the general drug price revaluation. There are many concerns that the biological equivalent test, which was conducted with the aim of maintaining drug prices, could lead to a reduction in dru
- Policy
- Antiepileptic perampanel’s adverse event rate at 32%
- by Lee, Hye-Kyung Jul 5, 2022 05:59am
- Results of the 6-year post-marketing surveillance (PMS) on the antiepileptic ingredient perampanel showed that 17 cases of serious adverse reactions whose causal relationship cannot be ruled out were reported. As 287 cases of unexpected adverse reactions whose causal relationship cannot be ruled out were also reported, the indication for
- Policy
- The revaluation of Streptokinase could be maintained for 1yr
- by Lee, Tak-Sun Jul 5, 2022 05:59am
- The pharmaceutical industry expects some components to be suspended in this year's benefit revaluation. The benefit revaluation of Streptokinase and Streptodornase, which are scheduled to submit a report on clinical revaluation results next year, could be suspended for one year. However, the final plan is expected to be decided through delibe
- Company
- Sanofi & MDsquare co-promote Digital Healthcare Business
- by Jul 5, 2022 05:58am
- Sanofi Korea Corporation announced on the 4th that it held a (MOU) signing ceremony with MDsquare to promote digital healthcare business on the 30th of last month. With this agreement, Sanofi provides chronic disease management and prevention information, and MDsquare develops premium health care programs to cooperate so that patients with
- Company
- RDK introduces monkeypox PCR test kits to Korea
- by Jul 5, 2022 05:58am
- On the 4th, Roche Diagnostics Korea announced that it had introduced PCR diagnostics kits for the detection of the monkeypox virus in Korea. The three kits that were introduced to Korea this time -▲ LightMix Modular Orthopox Virus, ▲ LightMix Modular Monkeypox Virus, and ▲ LightMix Modular Orthopox Virus typing1- were developed by Roch
- Policy
- Support for online conferences will be extended for 1 yr
- by Kim, Jung-Ju Jul 5, 2022 05:58am
- On-off events can be supported on an offline basis if certain conditions are met Temporary support for online academic conferences in medical, pharmaceutical, and medical devices will be extended for another year. This is because infectious diseases such as COVID-19 and monkeypox continue to occur, leaving room for reinforcement of social dis
- InterView
- "Leclaza’s mOS data of 38.9 months is remarkable"
- by Kim, Jin-Gu Jul 4, 2022 05:55am
- “The fact that Leclaza (lasertinib) achieved an OS (overall survival) of over 3 years is remarkable.” New OS data on the homegrown novel lung cancer drug Leclaza that was presented at the AOS 2022 & KCA Annual Meeting 2022 that was held recently in Seoul drew the pharmaceutical industry's attention. The results were from a trial that eva
